VRX
Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International Inc historical holders
total: 14
Greenbrier Partners Capital Management Valeant Pharmaceuticals International Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2014 Q4
Greenbrier Partners Capital Management has been an institutional investor in Valeant Pharmaceuticals International Inc (VRX) since 2014 Q3. According to 2026 Q2 report, Greenbrier Partners Capital Management doesn't hold any shares. The fund/company first acquired VRX in 2014 Q3, initially purchasing 20,000 shares. Since the initial investment, Greenbrier Partners Capital Management has made 1 more transaction in this position.
When did Greenbrier Partners Capital Management exit their VRX position?
Greenbrier Partners Capital Management no longer holds Valeant Pharmaceuticals International Inc (VRX). They sold off their entire position in 2014 Q4, closing out an investment that began in 2014 Q3.
When did Greenbrier Partners Capital Management first invest in VRX?
Greenbrier Partners Capital Management first invested in Valeant Pharmaceuticals International Inc (VRX) in 2014 Q3 at the reported quarter-end price of $131.20 per share, acquiring 20,000 shares in their initial purchase.
What is Greenbrier Partners Capital Management's average cost basis for VRX?
Based on historical transaction data, Greenbrier Partners Capital Management's estimated cost basis for Valeant Pharmaceuticals International Inc (VRX) is approximately $131.20 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $131.20
- Weighted AVG sell price:
- $131.20
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.